Literature DB >> 17932829

Duration of influenza A virus shedding in hospitalized patients and implications for infection control.

Surbhi Leekha1, Nicole L Zitterkopf, Mark J Espy, Thomas F Smith, Rodney L Thompson, Priya Sampathkumar.   

Abstract

OBJECTIVE: To assess the duration of shedding of influenza A virus detected by polymerase chain reaction (PCR) and cell culture among patients hospitalized with influenza A virus infection.
SETTING: Mayo Clinic (Rochester, Minnesota) hospitals that cater to both the community and referral populations.
METHODS: Patients 18 years old and older who were hospitalized between December 1, 2004, and March 15, 2005, with a laboratory-confirmed (ie, PCR-based) diagnosis of influenza A virus infection were consecutively enrolled. Additional throat swab specimens were collected at 2, 3, 5, and 7 days after the initial specimen (if the patient was still hospitalized). All specimens were tested by PCR and culture (both conventional tube culture and shell vial assay). Information on demographic characteristics, date of symptom onset, comorbidities, immunosuppression, influenza vaccination status, and receipt of antiviral treatment was obtained by interview and medical record review. Patients were excluded if informed consent could not be obtained or if the date of symptom onset could not be ascertained.
RESULTS: Of 149 patients hospitalized with influenza A virus infection, 50 patients were enrolled in the study. Most patients were older (median age, 76 years), and almost all (96%) had underlying chronic medical conditions. Of 41 patients included in the final analysis, influenza A virus was detected in 22 (54%) by PCR and in 12 (29%) by culture methods at or beyond 7 days after symptom onset. All 12 patients identified by culture also had PCR results positive for influenza A virus.
CONCLUSION: Hospitalized patients with influenza A virus infection can shed detectable virus beyond the 5- to 7-day period traditionally considered the duration of infectivity. Additional research is needed to assess whether prolonging the duration of patient isolation is warranted to prevent nosocomial outbreaks during the influenza season.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932829     DOI: 10.1086/520101

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  50 in total

1.  [Vaccination against pneumococci and influenza. How good is the evidence?].

Authors:  B Babouee; A F Widmer; M Battegay
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

2.  Whole genome sequencing identifies influenza A H3N2 transmission and offers superior resolution to classical typing methods.

Authors:  Dominik M Meinel; Susanne Heinzinger; Ute Eberle; Nikolaus Ackermann; Katharina Schönberger; Andreas Sing
Journal:  Infection       Date:  2017-10-31       Impact factor: 3.553

3.  [Influenza: special aspects in old age].

Authors:  A Kwetkat; A Leischker; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2018-06-27       Impact factor: 1.281

4.  Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.

Authors:  Nayer Khazeni; David W Hutton; Alan M Garber; Douglas K Owens
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

5.  A primer on strategies for prevention and control of seasonal and pandemic influenza.

Authors:  Scott Santibañez; Anthony E Fiore; Toby L Merlin; Stephen Redd
Journal:  Am J Public Health       Date:  2009-10       Impact factor: 9.308

6.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

7.  Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.

Authors:  Nayer Khazeni; David W Hutton; Alan M Garber; Nathaniel Hupert; Douglas K Owens
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

8.  Mathematical modeling of the effectiveness of facemasks in reducing the spread of novel influenza A (H1N1).

Authors:  Samantha M Tracht; Sara Y Del Valle; James M Hyman
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

Review 9.  Clinical review: primary influenza viral pneumonia.

Authors:  Jordi Rello; Aurora Pop-Vicas
Journal:  Crit Care       Date:  2009-12-21       Impact factor: 9.097

10.  Clinical and epidemiologic characteristics of 3 early cases of influenza A pandemic (H1N1) 2009 virus infection, People's Republic of China, 2009.

Authors:  Cao Bin; Li Xingwang; Shu Yuelong; Jiang Nan; Chen Shijun; Xu Xiayuan; Wang Chen
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.